Bruderman Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bruderman Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,366	Closed	-$37K	–	522
2019 Q1	$37K	Hold	2,366	–	–	0.01%	305
2018 Q4	$36K	Buy	2,366 +2,262	+2,175%	+$46.4K	0.01%	281
2018 Q3	$2K	Buy	104 +42	+68%	+$975	﹤0.01%	338
2018 Q2	$2K	Hold	62	–	–	﹤0.01%	354
2018 Q1	$1K	Buy	+62	New	+$1.21K	﹤0.01%	345
2017 Q3	–	Sell	-62	Closed	-$2K	–	298
2017 Q2	$2K	Buy	+62	New	+$1.92K	﹤0.01%	347
2017 Q1	–	Sell	-62	Closed	-$2K	–	296
2016 Q4	$2K	Sell	62 -315	-84%	-$12.6K	﹤0.01%	350
2016 Q3	$17K	Buy	377 +1	+0.3%	+$52	0.01%	296
2016 Q2	$19K	Buy	376 +2	+0.5%	+$106	0.01%	271
2016 Q1	$20K	Buy	374 +2	+0.5%	+$117	0.01%	270
2015 Q4	$24K	Buy	372 +1	+0.3%	+$62	0.01%	270
2015 Q3	$21K	Buy	371 +309	+498%	+$20K	0.01%	277
2015 Q2	$4K	Hold	62	–	–	﹤0.01%	399
2015 Q1	$4K	Buy	+62	New	+$3.6K	﹤0.01%	388

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bruderman Asset Management's TEVA Position: Q2 2019 in Review

Bruderman Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 2,366 shares — an estimated $37K sold.

Bruderman Asset Management first reported a position in TEVA in Q1 2015 and held it in 14 quarters. The position peaked at $37K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Bruderman Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Bruderman Asset Management sold 2,366 Teva Pharmaceuticals shares in Q2 2019, an estimated $37K.
Bruderman Asset Management first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 14 quarters.
Bruderman Asset Management's Teva Pharmaceuticals position peaked at $37K in Q1 2019.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.